PMID-sentid	Pub_year	Sent_text		comp_official_name	comp_offsetprotein_name	organism	prot_offset
30547679-8	2019	In terms of health outcomes, FTD/TPI was associated with 0.25 and 0.11 increment in LYs compared with BSC and regorafenib, respectively.	regorafenib	110-121	triosephosphate isomerase 1	Homo sapiens	33-36	
31838590-1	2020	BACKGROUND: Although regorafenib or trifluridine/tipiracil (FTD/TPI) has been recognized as a later-line standard treatment in patients with metastatic colorectal cancer (mCRC), not all patients have beneficial outcomes.	regorafenib	21-32	triosephosphate isomerase 1	Homo sapiens	64-67	
30547679-9	2019	Furthermore, FTD/TPI was associated with 0.17, and 0.07 increment in QALYs compared with BSC and regorafenib, resulting in ICERs of $32,759 per LY gained and $49,326 per QALY gained versus BSC.	regorafenib	97-108	triosephosphate isomerase 1	Homo sapiens	17-20	
30257515-9	2018	Treatment results following regorafenib administration subsequent to FTD or FTD/TPI suggest that sequential therapy with FTD/TPI prior to regorafenib may be effective in a clinical setting.	regorafenib	28-39	triosephosphate isomerase 1	Homo sapiens	125-128